Brief: Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49
BRIEF-Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49 Oct 11 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA - EFZIMFOTASE ALFA SHOWS IMPROVEMENT IN PRIMARY AND KEY SECONDARY ENDPOINTS AT WEEK 25 AND WEEK 49
Source text: ID:nWkr4j8yfc
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)